Authors/Disclosures
|
Alirexa Faridar, MD
(Methodist Neurological Institute)
|
Dr. Faridar has nothing to disclose. |
|
Tigran Kesayan, MD
(VUMC Pain Medicine and Neurology)
|
Dr. Kesayan has nothing to disclose. |
|
Jennifer A. Roggenbuck, MS, CGC
(Ohio State University)
|
The institution of Ms. Roggenbuck has received research support from Packard Foundation. |
|
Eliot A. Licht, MD
(VA Greater Los Angeles Healthcare System)
|
No disclosure on file |
|
Eliot A. Licht, MD
(VA Greater Los Angeles Healthcare System)
|
No disclosure on file |
|
|
No disclosure on file |
|
|
No disclosure on file |
|
Michael K. Hehir II, MD
(Larner College of Medicine at the University of Vermont)
|
Dr. Hehir has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Argenx. Dr. Hehir has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Alexion. Dr. Hehir has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for UCB Pharma. Dr. Hehir has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Janssen. Dr. Hehir has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Immunovant. Dr. Hehir has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Continuum- American Academy of Neurology. Dr. Hehir has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for MedLink Neurology. The institution of Dr. Hehir has received research support from Myasthenia Gravis Foundation of America. The institution of Dr. Hehir has received research support from University of Vermont Medical Center. |
|
Kimberly L. Panizzon
|
No disclosure on file |
|
Stanley J. Iyadurai, MD, PhD, FAAN
(Johns Hopkins All Children's Hospital/Catalyst)
|
Dr. Iyadurai has received personal compensation for serving as an employee of Catalyst Pharmaceuticals. Dr. Iyadurai has received stock or an ownership interest from Catalyst Pharmaceuticals. |